Gavin Hui • UCLA Profiles (original) (raw)

  1. Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes. Aesthetic Plast Surg. 2026 Mar; 50(5):1873-1880. Yesantharao PS, Shaheen MS, Hui G, Gombar S, Momeni A. PMID: 41258921.
    View in: PubMed Mentions: Fields:
  2. Unchecked Immunity to Unleashed Anarchy: A Case of Hemophagocytic Lymphohistiocytosis Following Combination Immune Checkpoint Inhibitor Therapy. Cureus. 2025 Aug; 17(8):e90533. Dommaraju SR, Stefanoudakis D, Hui G, Drakaki A. PMID: 40978875; PMCID: PMC12446752.
    View in: PubMed Mentions:
  3. Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes. Clin Genitourin Cancer. 2025 Aug; 23(4):102356. Bakaloudi DR, Talukder R, Enright T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Latchford C, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, Johnson J, Zakharia Y, Alva A, Nguyen CB, Hui G, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Barrera RM, Marmolejo D, McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F, Gupta S, Wright JL, Khaki AR, Grivas P. PMID: 40378559.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  4. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. J Immunother Cancer. 2025 Mar 03; 13(3). Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. PMID: 40032601; PMCID: PMC11877189.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  5. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Dec; 22(6):102198. Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgic J, Miletic M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. PMID: 39241315.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  6. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023 12 06; 115(12):1605-1615. El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. PMID: 37563779; PMCID: PMC11032703.
    View in: PubMed Mentions: 25 Fields:
    Translation:Humans
  7. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma. Curr Oncol. 2023 08 04; 30(8):7398-7411. Hui G, Stefanoudakis D, Zektser Y, Isaacs DJ, Hannigan C, Pantuck AJ, Drakaki A. PMID: 37623017; PMCID: PMC10452970.
    View in: PubMed Mentions: 6 Fields:
    Translation:Humans
  8. The Potential Revolution of Cancer Treatment with CRISPR Technology. Cancers (Basel). 2023 Mar 17; 15(6). Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, Zhang S, Hui G, Tabatabaei YA, Zektser Y, Lopez LP, Pantuck A, Drakaki A. PMID: 36980699; PMCID: PMC10046289.
    View in: PubMed Mentions: 25
  9. Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. Life (Basel). 2022 Mar 02; 12(3). Hui G, Drolen C, Hannigan CA, Drakaki A. PMID: 35330111; PMCID: PMC8949122.
    View in: PubMed Mentions: 1
  10. Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Leuk Lymphoma. 2021 06; 62(6):1510-1513. Ladha A, Hui G, Cheung E, Berube C, Coutre SE, Gotlib J, Liedtke M, Zhang TY, Muffly L, Mannis GN. PMID: 33491527.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  11. Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era. Case Rep Oncol Med. 2019; 2019:8349793. Hui G, Ghafouri SN, Shen J, Liu S, Drakaki A. PMID: 31019822; PMCID: PMC6452553.
    View in: PubMed Mentions: 11
  12. Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma. Clin Pract. 2018 Oct 26; 8(4):1097. Ehrlich D, Phan J, Hui G, Drakaki A. PMID: 30613373; PMCID: PMC6291742.
    View in: PubMed Mentions:
  13. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clin Genitourin Cancer. 2018 04; 16(2):e269-e276. Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. PMID: 29199023.
    View in: PubMed Mentions: 34 Fields:
    Translation:HumansCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs